Daiichi Sankyo SWOT Analysis, Competitors & USP

Daiichi Sankyo

Pharmaceutical

Pharma and Healthcare

Passion for innovation, Compassion for patients

It is one of the largest pharmaceutical company in Japan

Oncology & Cardiovascular diseases

Healthcare professionals offereing treatments to patients suffering from cancer or cardiovascular disease

They are global pharma innovator who aim to provide pharmaceuticals in shortest possible time

Below is the Strengths, Weaknesses, Opportunities & Threats (SWOT) Analysis of Daiichi Sankyo. Strengths are:

1. Has a strong workforce of over 30,000 employees

2. Leading producer of Benicar which is angiotensin II receptor antagonist

3. It is one of the largest pharmaceutical company in Japan

4. Strong presence in US, Europe, India, China, Brazil, Thailand and some others
5. Strong brand establishment through many major acquisitions

Here are the weaknesses in the Daiichi Sankyo SWOT Analysis:

1. Despite being a strong brand, had a limited market share due to international competitors

2. Operates in limited segments such as Oncology & Cardiovascular segment

Following are the Opportunities in Daiichi Sankyo SWOT Analysis:

1. Increasing world population and more awareness about health

2. More people suffering from chronic diseases such as cancer, cardiovascular diseases

3. Increasing awareness of healthcare solutions

The threats in the SWOT Analysis of Daiichi Sankyo are as mentioned:

1. Natural disasters in Japan

2. increasing stringency in drug development guidelines

3. Global economic slowdown

Below are the top 4 Daiichi Sankyo competitors:

1. Takeda Pharmaceuticals
2. Teva pharmaceuticals

3. Astellas pharmaceuticals

4. AstraZeneca